Lineage Cell Therapeutics Inc
TASE:LCTX
Relative Value
The Relative Value of one LCTX stock under the Base Case scenario is hidden ILS. Compared to the current market price of 495 ILS, Lineage Cell Therapeutics Inc is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
LCTX Competitors Multiples
Lineage Cell Therapeutics Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
L
|
Lineage Cell Therapeutics Inc
TASE:LCTX
|
391.6m ILS | 8.6 | -2 | -3.3 | -3.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.3B USD | 6 | 88 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.4B USD | 5.2 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.3B USD | 6 | 20.6 | 12.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.7B USD | 9.6 | 29 | 21.8 | 22.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 5.5 | 17.5 | 12.9 | 14.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
64.7B AUD | 3 | 33 | 11 | 13.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36.5B EUR | 10.4 | 33.4 | 36.1 | 36.9 |